Navigation Links
First trial in patients with a potential treatment of the incurable ALS muscle disease
Date:12/1/2008

r the group of Diether Lambrechts, Wim Robberecht and Peter Carmeliet showed that persons who produce too little VEGF − due to certain variations in the gene that codes for VEGF − have a higher risk of developing ALS. This was the starting point of a search for a possible treatment with the VEGF protein.

Testing the treatment on rats with a severe form of ALS and on rats with a milder form, the researchers found that, in both groups, the VEGF-treated rats manifested the disease later than the untreated animals, and they lived considerably longer.

Using a pump

The researchers also investigated what the optimal technique would be for administering VEGF. An ordinary injection proved to be ineffective. But continuous administration of the VEGF protein directly into the cerebrospinal fluid (the fluid that circulates around the brain and the spinal cord) was quite effective. This was possible by means of a small pump that continuously pumps the VEGF protein in the brain. Furthermore, this technique permits a patient-oriented approach by enabling the administered dose of the VEGF protein to be easily controlled.

A story with several players

These encouraging and promising results were only the first steps on the way to a new remedy. Anders Haegerstrand and his team of the Swedish company NeuroNova have taken the development of the treatment further. After additional studies this research has reached the stage of starting the first trial in

patients. Wim Robberecht (UZ Leuven) and Markus Jerling (NeuroNova) will co-ordinate this first trial which is intended to evaluate the safety and tolerability of the drug and the infusion system. It is planned to start at the end of this year, and the investigator Dr Robberecht is currently looking for patients who are eligible for participation. These regulated studies on ALS patients will have to demonstrate the safety of the VEGF administration, and in a l
'/>"/>

Contact: Sooike Stoops
sooike.stoops@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Dictyostelium cells shown to lay breadcrumb trail as first step in multicellular formation
2. Caltech researchers get first 3-D glimpse of bacterial cell-wall architecture
3. Planetary first family discovered by astronomers using Gemini and Keck Observatories
4. Planetary "first family" discovered by astronomers using Gemini and Keck Observatories
5. First at-home test for vasectomized men proves to be safe, accurate
6. Washington University scientists first to sequence genome of cancer patient
7. First results from hospital trials testing
8. Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska
9. First comprehensive genomic study of common cold reveals new treatment targets
10. Synaptics Reports Record Results for First Quarter of Fiscal 2009
11. Study of polar dinosaur migration questions whether dinosaurs were truly the first great migrators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San ... catalyst that provides the connective tissue that enhances care ... them to easily share client-level information; earned a second ... expand to organizations serving seniors aging in community and; ... partner on December 11 th 4-6p. ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... A new University of Minnesota study reveals that ... wastewater treated by the highest-quality treatment technology ... of antibiotic-resistant bacteria, often referred to as "superbacteria," ... that wastewater treated using standard technologies probably contains ...
... to be published in the journal GENETICS ( http://www.genetics.org ... of research knowledge obtained on an important experimental organism ... be authored by top geneticists from around the world ... research and its applications to human health and well-being. ...
... PROVIDENCE, R.I. [Brown University] In a new study, ... metabolism, and improved the efficacy of insulin in mice ... in their fat tissue. Although the obesity prevention came ... offers new clues about the connections among obesity, insulin ...
Cached Biology News:New study finds that even the cleanest wastewater contributes to more 'super bacteria' 2YeastBook, the Eukaryotic Cell Encyclopedia is launched by Genetics 2Enzyme boosts metabolism, prevents weight gain in mice 2
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... 18, 2014 Reports from CDC ... States suffer from one or more chronic health conditions ... Medication can address some of these diseases, but may ... many sufferers face. While implanted nerve stimulation devices today ... whole nerve, which can induce side effects. , ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... equity stake in Zenotech Laboratories to 45%, GURGAON, ... Laboratories Limited (Zenotech) today announced the,signing of Definitive Agreements, ... its current 7% to 45% at a price of ... involves: (a) Purchase of shares from the existing ...
... Monday, October 8, at 2:15 ... p.m. ... Sciences Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceutical,company engaged in the ... respiratory diseases and,cancer, is scheduled to present at the Natixis Bleichroeder Hidden ...
... 3 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM ... President and Chief,Executive Officer, is scheduled to present ... 2:45pm PDT/5:45pm EDT on Wednesday, October 10. ... and can be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ...
Cached Biology Technology:Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 2Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 3Advanced Life Sciences to Present at Natixis Bleichroeder Hidden Gems Conference 2
Request Info...
... Epitope: aa 16-25 of human GSK3 alpha. ... Store vial at -20 C prior to opening. ... contents and freeze at -20 C or below. Avoid ... Other Sub-Family: not assigned-Other ...
... powder containing carbohydrate and citrate buffer ... One unit will convert 1.0 mole ... D -glucose 6-phosphate per min ... Chem comp: Protein ~ ...
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
Biology Products: